Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey
PEDIATRIC PULMONOLOGY, cilt.55, sa.9, ss.2302-2306, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 55 Sayı: 9
- Basım Tarihi: 2020
- Doi Numarası: 10.1002/ppul.24854
- Dergi Adı: PEDIATRIC PULMONOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
- Sayfa Sayıları: ss.2302-2306
- Anahtar Kelimeler: cystic fibrosis, modulator drugs, national registry, TEZACAFTOR-IVACAFTOR
- Eskişehir Osmangazi Üniversitesi Adresli: Evet
Özet
Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.